

## Supplementary data

### **Design, synthesis, biological evaluation, and docking studies of novel triazolo[4,3-*b*]pyridazine derivatives as dual cMet/Pim-1 potential inhibitors with antitumor activity**

Mohamed E. Mahmoud<sup>1</sup>, Eman M. Ahmed<sup>2</sup>, Hamdy M. Ragab<sup>2</sup>, Rania Farag A. Eltelbany<sup>3</sup>, Rasha A. Hassan<sup>2,\*</sup>

1 Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Modern University for Technology and Information (MTI), Cairo, Egypt

2 Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt

3 Department of Biochemistry, Faculty of Pharmacy, Modern University for Technology and Information (MTI), Cairo, Egypt

**Correspondence to:** Rasha A. Hassan, Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

Address: 33 Kasr El-Aini Street, Cairo, Egypt.

E-mail: [rasha.hasan@pharma.cu.edu.eg](mailto:rasha.hasan@pharma.cu.edu.eg)

ORCID: 0000-0002-6785-6394

## Supplementary data

### (Biological evaluation- Molecular modelling- Chemistry)

#### I- Biological evaluation

##### Antiproliferative Activity

Assay Human carcinoma cell lines were obtained from the International Center for Training and Advanced Research (ICTAR), (Cairo, Egypt), purchased from the American Type Culture Collection (VA, USA). Eagle's Minimum Essential Medium was used to culture MCF-7 cells, fetal bovine serum was added to the medium at a final concentration of 10%. Culture plates and flasks were treated with penicillin (100 U/mL) and streptomycin (100 mg/mL) (SPL Life Sciences, Korea). Cells were kept at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> (Thermo Electron Corporation, Forma series II, 3141, USA). An inverted microscope was used to examine the confluence of cells and proceeded with the MTT assay (Zeiss, Axiovert 40- CFL, Gottingen, Germany).

##### MTT cytotoxicity assay and selectivity index (SI) calculation

Cell viability, which express the cytotoxic property of the compounds **4a** and **4g**, which was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) colorimetric assay as mentioned previously by Somarathna et al. Cells (density 1.2–1.8, 10,000 cells/well) were placed in a 96-well plate for 24 h before the MTT assay in a volume of 100 µL complete growth medium + 100 ul of the tested compound per well. 20 mL of MTT solution (5 mg/mL in PBS) was added to each well and incubated for 3 h at 37°C. After removing the medium, 100 mL of DMSO was added to each well for dissolving the purple formazan product (Sigma-Aldrich, St. Louis, MO, USA). A 96-well plate reader was used to measure the absorbance at 570 nm and 630 nm (Bio-Rad, Hercules USA). These data were used to calculate the percentage inhibition and the IC<sub>50</sub>, which is defined as the concentration of the test substance at which cell viability declines to 50%. The IC<sub>50</sub> values [the concentration required for 50% inhibition of cell viability] were calculated using sigmoidal dose-response curve-fitting models. The selectivity index (SI) was calculated as the ratio of cytotoxicity (IC<sub>50</sub>) on normal cells (MCF10a) to cancer cells (MCF7).

##### c-Met Kinase Inhibition Assay

The assay is designed to measure c-Met kinase activity for screening and profiling applications using Kinase-Glo® MAX as a detection reagent (BPS Bioscience, #79559). The assay kit comes in a convenient 96-well format.

##### Pim-1 Kinase Inhibition Assay

Kinase enzymatic activities were assayed with 10 µM ATP in 384-well plates using the luminescent ADP-Glo™ assay (Promega, Madison, WI, USA) according to the recommendations of the manufacturer. The transmitted signal was measured using the Envision (PerkinElmer, Waltham, MA, USA) microplate

luminometer and expressed in Relative Light Unit (RLU). To determine the half maximal inhibitory concentration ( $IC_{50}$ ), the assays were performed in duplicate in the absence or presence of increasing doses of the tested compounds.

### **Human Phosphorylated Type of PI3K ELISA Kit**

We used an Enzyme-Linked Immunosorbent Assay (ELISA-MBS167579). The plate has been pre-coated with human P-PI3K antibody. P-PI3K present in the sample is added and binds to antibodies coated on the wells. And then biotinylated human P-PI3K Antibody is added and binds to P-PI3K in the sample. Then Streptavidin-HRP is added and binds to the Biotinylated P-PI3K antibody. After incubation, unbound Streptavidin-HRP is washed away during a washing step. The substrate solution is then added, and color develops in proportion to the amount of human P-PI3K. The reaction is terminated by the addition of an acidic stop solution and absorbance is measured at 450 nm.

### **Phospho-Akt**

Sandwich ELISA to measure human Akt phosphorylated at S473 in cell lysates was developed. Using DuoSet® IC ELISA: (DYC887B-2) (R&D System, USA) according to the manufacturer's introductions. An immobilized capture antibody specific for Akt1 binds both phosphorylated and unphosphorylated proteins. After washing away unbound material, a biotinylated detection antibody specific for Akt1 phosphorylated at S473 is used to detect only phosphorylated protein, utilizing a standard Streptavidin HRP format.

### **Phospho-mTOR**

Sandwich ELISA kit for the measurement of human phospho-mTOR and total mTOR (Abcam). An anti-pan mTOR antibody has been coated onto a 96-well plate. Samples are pipetted into the wells and mTOR present in a sample is bound to the wells by the immobilized antibody and the wells are washed. In select wells, rabbit anti-phospho mTOR (S2448) antibody is added to detect phosphorylated mTOR. In the remaining wells, the biotinylated anti-pan-mTOR antibody is used to detect pan mTOR. After washing away unbound antibodies, HRP-conjugated anti-rabbit IgG or HRP-conjugated Streptavidin is pipetted into the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of mTOR (S2448). The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.

### **Cell cycle analysis**

Flow cytometry was used to analyze the cell cycle using ab139418 propidium iodide flow cytometry kit/BD (Abcam, Cambridge, UK), as directed by the manufacturer guidelines. MCF7 cells were treated with compound **4g** at its  $IC_{50}$  concentration for 24 h. The cells were washed twice with ice-cold phosphate buffer saline (PBS) and collected by centrifugation. The cells were then fixed using ice-cold 66% (v/v) ethanol, washed with PBS, and re-suspended with 0.1 mg/mL RNase to digest cellular RNA and thus minimize stained RNA in the background. The cells were next stained with PI, a fluorescent molecule that may bind to

nucleic acid, at a concentration of 40 mg/mL. In cells, PI attaches to DNA in proportion to its amount. Because the DNA content of cells at different stages of the cell cycle differs, the fluorescence intensity can be used to assess the stage of cell growth. FACS Calibur (BD Biosciences, USA) was used to estimate cell fluorescence, which was then examined using Cell-Quest software (Becton Dickinson). Cell cycle analysis of MCF7 cells without any treatment was used as a control.

### **Annexin V-FITC assay for assessing apoptosis**

After treatments, apoptotic cells were measured using the annexin V-FITC Apoptosis Detection Kit (BioVision) (K101-25). In a six-well plate with a cell density of  $5 \times 10^5$  cells/well, MCF7 cells were incubated for 24 h at 37°C. After the incubation period, the cells were centrifuged and resuspended in 500  $\mu$ l of 1X binding buffer. Then, at room temperature for 5 minutes, 5  $\mu$ L of annexin V-FITC and propidium iodide (PI) (BD Bioscience) were added, followed by incubation in the dark. Flow cytometry using FITC signal (usually FL1) and PI staining by the phycoerythrin emission signal detector (usually FL2).

### **Caspase-9 activity determination**



The activity of caspase-9 was determined using the Invitrogen Caspase-9 (active) Human ELISA, (USA, KHO-1091). To detect and quantify the level of human active caspase-9 protein the detailed procedure including the standard curve preparation was described in the manufacturer's instructions. All the experiments were performed in triplicate.

## **II- Molecular modeling**

### **Physicochemical, pharmacokinetic, and ADME properties**

Molecular properties of the most potent triazolo pyridazine derivatives **4a** and **4g** using the SwissADME website.

4a

SMILES Oc1ccc(cc1)/C=N/Nc1ccc2n(n1)c(nn2)c1ccccc1

## Physicochemical Properties

Formula	C <sub>18</sub> H <sub>14</sub> N <sub>6</sub> O
Molecular weight	330.34 g/mol
Num. heavy atoms	25
Num. arom. heavy atoms	21
Fraction Csp <sup>3</sup>	0.00
Num. rotatable bonds	4
Num. H-bond acceptors	5
Num. H-bond donors	2
Molar Refractivity	95.72
TPSA <sup>2</sup>	87.70 Å <sup>2</sup>

## Lipophilicity

Log <i>P</i> <sub>o/w</sub> (iLOGP) <sup>2</sup>	1.91
Log <i>P</i> <sub>o/w</sub> (XLOGP3) <sup>2</sup>	3.00
Log <i>P</i> <sub>o/w</sub> (WLOGP) <sup>2</sup>	2.75
Log <i>P</i> <sub>o/w</sub> (MLOGP) <sup>2</sup>	2.70
Log <i>P</i> <sub>o/w</sub> (SILICOS-IT) <sup>2</sup>	1.94
Consensus Log <i>P</i> <sub>o/w</sub> <sup>2</sup>	2.46

## Water Solubility

Log S (ESOL) <sup>2</sup>	-4.14
Solubility	2.42e-02 mg/ml ; 7.32e-05 mol/l
Class <sup>2</sup>	Moderately soluble
Log S (Ali) <sup>2</sup>	-4.51
Solubility	1.03e-02 mg/ml ; 3.12e-05 mol/l
Class <sup>2</sup>	Moderately soluble
Log S (SILICOS-IT) <sup>2</sup>	-5.92
Solubility	3.99e-04 mg/ml ; 1.21e-06 mol/l
Class <sup>2</sup>	Moderately soluble

## Pharmacokinetics

GI absorption <sup>2</sup>	High
BBB permeant <sup>2</sup>	No
P-gp substrate <sup>2</sup>	No
CYP1A2 inhibitor <sup>2</sup>	Yes
CYP2C19 inhibitor <sup>2</sup>	Yes
CYP2C9 inhibitor <sup>2</sup>	No
CYP2D6 inhibitor <sup>2</sup>	No
CYP3A4 inhibitor <sup>2</sup>	No
Log <i>K</i> <sub>p</sub> (skin permeation) <sup>2</sup>	-6.19 cm/s



## Druglikeness

Lipinski <sup>2</sup>	Yes; 0 violation
Ghose <sup>2</sup>	Yes
Veber <sup>2</sup>	Yes
Egan <sup>2</sup>	Yes
Muegge <sup>2</sup>	Yes
Bioavailability Score <sup>2</sup>	0.55

## Medicinal Chemistry

PAINS <sup>2</sup>	1 alert: hzone_phenol_B <sup>2</sup>
Brenk <sup>2</sup>	1 alert: imine_1 <sup>2</sup>
Leadlikeness <sup>2</sup>	Yes
Synthetic accessibility <sup>2</sup>	3.25

4g



SMILES COC1CCC(CC1)C1NCC2N1NC(N/N=C/C1CCC(CC1)O)CC2

#### Physicochemical Properties

Formula	C19H16N6O2
Molecular weight	360.37 g/mol
Num. heavy atoms	27
Num. arom. heavy atoms	21
Fraction Csp3	0.05
Num. rotatable bonds	5
Num. H-bond acceptors	6
Num. H-bond donors	2
Molar Refractivity	102.21
TPSA <sup>2</sup>	96.93 Å²

#### Lipophilicity

Log $P_{o/w}$ (iLOGP) <sup>2</sup>	2.22
Log $P_{o/w}$ (XLOGP3) <sup>2</sup>	2.97
Log $P_{o/w}$ (WLOGP) <sup>2</sup>	2.76
Log $P_{o/w}$ (MLOGP) <sup>2</sup>	2.42
Log $P_{o/w}$ (SILICOS-IT) <sup>2</sup>	1.98
Consensus Log $P_{o/w}$ <sup>2</sup>	2.47

#### Water Solubility

Log S (ESOL) <sup>2</sup>	-4.19
Solubility	2.32e-02 mg/ml ; 6.44e-05 mol/l
Class <sup>2</sup>	Moderately soluble
Log S (Ali) <sup>2</sup>	-4.67
Solubility	7.73e-03 mg/ml ; 2.14e-05 mol/l
Class <sup>2</sup>	Moderately soluble
Log S (SILICOS-IT) <sup>2</sup>	-6.03
Solubility	3.39e-04 mg/ml ; 9.42e-07 mol/l
Class <sup>2</sup>	Poorly soluble

#### Pharmacokinetics

GI absorption <sup>2</sup>	High
BBB permeant <sup>2</sup>	No
P-gp substrate <sup>2</sup>	No
CYP1A2 inhibitor <sup>2</sup>	Yes
CYP2C19 inhibitor <sup>2</sup>	No
CYP2C9 inhibitor <sup>2</sup>	Yes
CYP2D6 inhibitor <sup>2</sup>	No
CYP3A4 inhibitor <sup>2</sup>	No
Log $K_p$ (skin permeation) <sup>2</sup>	-6.39 cm/s

#### Druglikeness



Lipinski <sup>2</sup>	Yes; 0 violation
Ghose <sup>2</sup>	Yes
Veber <sup>2</sup>	Yes
Egan <sup>2</sup>	Yes
Muegge <sup>2</sup>	Yes
Bioavailability Score <sup>2</sup>	0.55

#### Medicinal Chemistry

PAINS <sup>2</sup>	1 alert: hzone_phenol_B <sup>2</sup>
Brenk <sup>2</sup>	1 alert: imine_1 <sup>2</sup>
Leadlikeness <sup>2</sup>	No; 1 violation: MW>350
Synthetic accessibility <sup>2</sup>	3.34


### III- <sup>1</sup>H NMR, <sup>13</sup>C NMR, and other spectral data of the new derivatives.

#### Compound 4a




Emad-Y4-H

Parameter	Value
1 Title	Emad-Y4-H
2 Origin	Bruker BioSpin GmbH
3 Owner	nmsu
4 Solvent	DMSO
5 Temperature	297.6
6 Experiment	1D
7 Probe	Z108618_0941 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	16
9 Relaxation Delay	1.0000
10 Acquisition Time	4.0894
11 Acquisition Date	2021-09-05T10:50:43
12 Modification Date	2021-09-05T10:50:43
13 Spectrometer Frequency	400.13
14 Spectral Width	8012.8
15 Lowest Frequency	-1535.6
16 Nucleus	<sup>1</sup> H
17 Spectral Size	65536
18 Absolute Reference	





Emad-Y4-C

Parameter	Value
1 Title	Emad-Y4-C
2 Origin	Bruker BioSpin GmbH
3 Owner	nmsu
4 Solvent	DMSO
5 Temperature	298.5
6 Experiment	1D
7 Probe	Z108618_0941 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	602
9 Relaxation Delay	2.0000
10 Acquisition Time	1.3631
11 Acquisition Date	2021-09-05T11:34:21
12 Modification Date	2021-09-05T11:34:22
13 Spectrometer Frequency	100.62
14 Spectral Width	24038.5
15 Lowest Frequency	-1958.0
16 Nucleus	<sup>13</sup> C
17 Spectral Size	65536
18 Absolute Reference	







# Compound 4b





Emad-Y8-H




Rasha Ahmed\_C\_Y8



# Compound 4c




Emad-Y7-H





Emad-Y7-C

Emad-Y7-C




# Compound 4d




Emad-Y1-H

Parameter	Value
1 Title	Emad-Y1-H
2 Origin	Bruker BioSpin GmbH
3 Owner	nmrsu
4 Solvent	DMSO
5 Temperature	297.7
6 Experiment	1D
7 Probe	Z108618_0941 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	16
9 Relaxation Delay	1.0000
10 Acquisition Time	4.0894
11 Acquisition Date	2021-09-05T10:09:51
12 Modification Date	2021-09-05T10:09:51
13 Spectrometer Frequency	400.13
14 Spectral Width	8012.8
15 Lowest Frequency	-1535.6
16 Nucleus	<sup>1</sup> H
17 Spectral Size	65536
18 Absolute Reference	




Emad-Y1-C

Parameter	Value
1 Title	Emad-Y1-C
2 Origin	Bruker BioSpin GmbH
3 Owner	nmrsu
4 Solvent	DMSO
5 Temperature	298.5
6 Experiment	1D
7 Probe	Z108618_0941 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	484
9 Relaxation Delay	2.0000
10 Acquisition Time	1.3631
11 Acquisition Date	2021-09-05T10:44:03
12 Modification Date	2021-09-05T10:44:03
13 Spectrometer Frequency	100.62
14 Spectral Width	24038.5
15 Lowest Frequency	-1958.0
16 Nucleus	<sup>13</sup> C
17 Spectral Size	65536
18 Absolute Reference	






Emad-Y2-H





Emad-Y2-C







# Compound 4f





Emad-Y6-H



Emad-Y6-C




# Compound 4g



Dr-Rasha Ahmed Y3


Emad-Y3-H

Parameter	Value
1 Title	Emad-Y3-H
2 Origin	Bruker BioSpin GmbH
3 Owner	nmrsu
4 Solvent	DMSO
5 Temperature	297.4
6 Experiment	1D
7 Probe	Z108618_09 41 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	16
9 Relaxation Delay	1.0000
10 Acquisition Time	4.0894
11 Acquisition Date	2021-09-07T 05:25:13
12 Modification Date	2021-09-07T 05:25:13
13 Spectrometer Frequency	400.13
14 Spectral Width	8012.8
15 Lowest Frequency	-1535.6
16 Nucleus	1H
17 Spectral Size	65536
18 Absolute Reference	





Emad-Y3-C  
Emad-Y3-C

Parameter	Value
1 Title	Emad-Y3-C
2 Origin	Bruker BioSpin GmbH
3 Owner	nmrsu
4 Solvent	DMSO
5 Temperature	298.1
6 Experiment	1D
7 Probe	Z108618_0941 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	1024
9 Relaxation Delay	2.0000
10 Acquisition Time	1.3631
11 Acquisition Date	2022-01-22T03:09:12
12 Modification Date	2022-01-22T03:09:12
13 Spectrometer Frequency	100.61
14 Spectral Width	24038.5
15 Lowest Frequency	-1958.0
16 Nucleus	13C
17 Spectral Size	65536
18 Absolute Reference	




# Compound 5




Emad-P1a 11 September-H

Parameter	Value
1 Title	Emad-P1a 11 September-H
2 Origin	Bruker BioSpin GmbH
3 Owner	nmrsu
4 Solvent	DMSO
5 Temperature	297.4
6 Experiment	1D
7 Probe	Z108618_0941 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	16
9 Relaxation Delay	1.0000
10 Acquisition Time	4.0894
11 Acquisition Date	2021-09-11T10:19:28
12 Modification Date	2021-09-11T10:19:28
13 Spectrometer Frequency	400.13
14 Spectral Width	8012.8
15 Lowest Frequency	-1535.6
16 Nucleus	<sup>1</sup> H
17 Spectral Size	65536
18 Absolute Reference	





Emad-P1a-C

Parameter	Value
1 Title	Emad-P1a-C
2 Origin	Bruker BioSpin GmbH
3 Owner	nmrsu
4 Solvent	DMSO
5 Temperature	298.1
6 Experiment	1D
7 Probe	Z108618_0941 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	761
9 Relaxation Delay	2.0000
10 Acquisition Time	1.3631
11 Acquisition Date	2022-01-02T05:57:09
12 Modification Date	2022-01-02T12:57:10
13 Spectrometer Frequency	100.62
14 Spectral Width	24038.5
15 Lowest Frequency	-1958.0
16 Nucleus	<sup>13</sup> C
17 Spectral Size	65536
18 Absolute Reference	




# Compound 6a




Emad-P3a-H  
Emad-P3a-H

Parameter	Value
1 Title	Emad-P3a-H
2 Origin	Bruker BioSpin GmbH
3 Owner	nmrsu
4 Solvent	DMSO
5 Temperature	297.4
6 Experiment	1D
7 Probe	Z108618_0941 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	16
9 Relaxation Delay	1.0000
10 Acquisition Time	4.0894
11 Acquisition Date	2021-09-12T11:41:12
12 Modification Date	2021-09-12T11:41:12
13 Spectrometer Frequency	400.13
14 Spectral Width	8012.8
15 Lowest Frequency	-1535.6
16 Nucleus	1H
17 Spectral Size	65536
18 Absolute Reference	





Emad-P3a-C

Parameter	Value
1 Title	Emad-P3a-C
2 Origin	Bruker BioSpin GmbH
3 Owner	nmrsu
4 Solvent	DMSO
5 Temperature	298.6
6 Experiment	1D
7 Probe	Z108618_0941 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	1024
9 Relaxation Delay	2.0000
10 Acquisition Time	1.3631
11 Acquisition Date	2021-09-18T10:09:13
12 Modification Date	2021-09-18T01:09:12
13 Spectrometer Frequency	100.62
14 Spectral Width	24038.5
15 Lowest Frequency	-1958.0
16 Nucleus	13C
17 Spectral Size	65536
18 Absolute Reference	






# Compound 6b



Emad-P3d-H  
Emad-P3d-H

Parameter	Value
1 Title	Emad-P3d-H
2 Origin	Bruker BioSpin GmbH
3 Owner	nmsu
4 Solvent	DMSO
5 Temperature	297.4
6 Experiment	1D
7 Probe	Z108618_0941 (PA BBO 400S1 BBF-H-D-05 Z)
8 Number of Scans	16
9 Relaxation Delay	1.0000
10 Acquisition Time	4.0894
11 Acquisition Date	2021-09-12T11:51:05
12 Modification Date	2021-09-12T11:51:05
13 Spectrometer Frequency	400.13
14 Spectral Width	8012.8
15 Lowest Frequency	-1535.6
16 Nucleus	<sup>1</sup> H
17 Spectral Size	65536
18 Absolute Reference	



Rasha Ahmed\_C\_P2C

Parameter	Value
1 Title	Rasha Ahmed_C_P2C
2 Origin	Bruker BioSpin GmbH
3 Owner	nmr
4 Solvent	DMSO
5 Temperature	298.0
6 Experiment	1D
7 Probe	5 mm PABBO BB/19F-1H/D Z-GRD Z108618/ 0610
8 Number of Scans	1200
9 Relaxation Delay	2.0000
10 Acquisition Time	1.3631
11 Acquisition Date	2022-05-10T16:51:00
12 Modification Date	2022-05-10T16:51:57
13 Spectrometer Frequency	100.64
14 Spectral Width	24038.5
15 Lowest Frequency	-1957.4
16 Nucleus	<sup>13</sup> C
17 Spectral Size	65536
18 Absolute Reference	

